SCHEMBL20135463

SCHEMBL20135463

Cc1ccc(C2(C(C)(C)C)NC(=O)NC2=O)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
B3GNT2 Q9NY97 1/20 0.36
ADAMTS5 Q9UNA0 6/20 0.34
MMP2 P08253 3/20 0.34
ADAM17 P78536 1/20 0.34
MMP14 P50281 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.32
TNF P01375 1/20 0.31
ELANE P08246 1/20 0.31
HPGDS O60760 1/20 0.31
CACNA1F O60840 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
HTR2A P28223 1/20 0.31
HRH1 P35367 1/20 0.31
SCN1A P35498 1/20 0.31
SCN4A P35499 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688518 1.00 B3GNT2 (0.36) B3GNT2ADAMTS5MMP2ADAM17MMP14
SCHEMBL20135575 0.78 MEN1 (0.48) B3GNT2ADAMTS5MMP2ADAM17MMP14
SCHEMBL542191 0.74 CYP2C9 (0.53) MMP2ADAM17CACNA1FALDH1A1MAPT
SCHEMBL20135620 0.73 B3GNT2 (0.34) B3GNT2ADAM17MAPT
SCHEMBL29688347 0.73 B3GNT2 (0.34) B3GNT2ADAM17MAPT
SCHEMBL17884490 0.68 ADAMTS5 (0.49) ADAMTS5MMP2ADAM17MMP14
SCHEMBL17884487 0.67 ADAMTS5 (0.54) ADAMTS5MMP2ADAM17MMP14
SCHEMBL25943917 0.67 ADAMTS5 (0.54) ADAMTS5MMP2ADAM17MMP14
SCHEMBL543015 0.59 MEN1 (0.49) MMP2ADAM17MMP14MEN1KMT2A
SCHEMBL20134878 0.59 LMNA (0.53) MMP2ADAM17MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 B3GNT2 1038/4885ADAMTS5 23/4885MMP2 4/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 B3GNT2 1394/4885ADAMTS5 25/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.